Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) EBT Margin (2022 - 2025)

Historic EBT Margin for bioAffinity Technologies (BIAF) over the last 4 years, with Q3 2025 value amounting to 349.08%.

  • bioAffinity Technologies' EBT Margin fell 2640600.0% to 349.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 216.89%, marking a year-over-year decrease of 1268800.0%. This contributed to the annual value of 96.43% for FY2024, which is 2161400.0% up from last year.
  • Latest data reveals that bioAffinity Technologies reported EBT Margin of 349.08% as of Q3 2025, which was down 2640600.0% from 317.59% recorded in Q2 2025.
  • bioAffinity Technologies' EBT Margin's 5-year high stood at 81.37% during Q1 2024, with a 5-year trough of 427752.87% in Q3 2022.
  • In the last 4 years, bioAffinity Technologies' EBT Margin had a median value of 333.34% in 2025 and averaged 48706.01%.
  • Over the last 5 years, bioAffinity Technologies' EBT Margin had its largest YoY gain of 2000000000bps in 2023, and its largest YoY loss of -20510100bps in 2023.
  • Quarter analysis of 4 years shows bioAffinity Technologies' EBT Margin stood at 71380.39% in 2022, then surged by 100bps to 107.12% in 2023, then dropped by -25bps to 134.4% in 2024, then crashed by -160bps to 349.08% in 2025.
  • Its EBT Margin was 349.08% in Q3 2025, compared to 317.59% in Q2 2025 and 143.06% in Q1 2025.